NK Cell Therapy for Recurrent Brain Tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Confirmed malignant brain tumor with imaging showing it's growing or has returned after prior treatment
- Good enough overall health to tolerate the therapy (Karnofsky score ≥60%)
- Completed prior cancer treatments (like chemotherapy or radiation) at least 4 weeks before joining, with minimal lingering side effects
- Blood counts, liver function, kidney function, and heart function all within acceptable ranges
- No active infections (including HIV, hepatitis B/C) and no uncontrolled serious illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests a new treatment using donated natural killer (NK) cells injected into the body to fight high-grade brain tumors. It might help people with certain types of aggressive gliomas that are newly diagnosed.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This early-phase trial tests injections of lab-grown immune cells directly into (or near) a brain tumor. It aims to see if the treatment is safe and can help control recurrent, progressive, or resistant CNS tumors.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.